What are the goals of pharmacotherapy in Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print
Answer

The goals of pharmacotherapy in patients with Crohn disease are to reduce morbidity, to prevent complications, and to maintain nutritional status.

More recently, investigators reported the first use of a validated electrospray ionization LC-MS/MS method in human plasma for the simultaneous quantification of up to seven monoclonal antibodies (adalimumab, cetuximab, infliximab, rituximab, secukinumab, tocilizumab, and trastuzumab) acting against different pharmacologic targets. [152] This method has the potential to open up the field of therapeutic drug monitoring to many monoclonal antibodies, including for adalimumab, in patients with Crohn disease. [152]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!